Replidyne, Inc. (NASDAQ: RDYN) was featured in the 24 September issue of BioCentury, The Bernstein Report on BioBusiness! The article features some of the companies earlier stage pipeline, particularly REP3123 a MetRS inhibitor in preclinical development that may be more effective for severe Clostridium difficile-associated diarrhea (CDAD) than ViroPharma (NASDAQ: VPHM) and Eli Lilly’s (NYSE: LLY) Vancocin® or possibly Pfizer’s (NYSE: PFE) Flagyl® for moderate CDAD.
Replidyne believes the advantages of REP3123 may lay in the ability to reduce the C. difficile’s sporulation and toxin production and, via its narrow spectrum of activity have less effect on gut flora.
“Sporulation is a major problem with C. difficile,” said Chief Scientific Officer Nebojsa Janjic. “The spores are a dry-dust form of the bacteria that can persist in the gut and the environment for a long time. If you reduce spores in both places, you can reduce relapse rates.”
We should anticipate an announcement before years end on clinical trial strategy for 2008.